Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Agilent Invests In Synthetic Bio Firm

by Ann M. Thayer
May 6, 2013 | A version of this story appeared in Volume 91, Issue 18

Agilent Technologies has invested $21 million and gained an equity stake in Gen9, a Cambridge, Mass.-based synthetic biology company. Gen9 will use the money to advance product development and expand its infrastructure for commercial-scale gene synthesis. Gen9 will also gain access to Agilent’s oligonucleotide library synthesis technology for making DNA libraries and pathway constructs. Researchers from MIT, Harvard Medical School, and Stanford University founded Gen9 in 2009.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.